“We are very pleased that now also women in the U.S. have the option to choose our new oral contraceptive Natazia as an effective option for the prevention of pregnancy.,” said Phil Smits, MD, Head of Bayer Schering Pharma´s business unit Women’s Healthcare. “We are also working with the FDA on an indication for menstrual bleeding disorders to offer women a tailored therapy for this debilitating condition”, Smits said.
About Natazia’s Clinical Program
US approval for the indication pregnancy prevention:
•
The first and only contraceptive to bring estradiol valerate together with dienogest in a new dosing regimenContraceptive reliability of Natazia was evaluated in two large studies and shown as effective as other marketed birth control pills.
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover, manufacture and market products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide.
No hay comentarios:
Publicar un comentario